Abstracts tagged "Biologic drugs"

Abstract Number: 2826 • 2019 ACR/ARP Annual Meeting
Risk of Serious Infections in Tofacitinib versus Other Biologic Drug Initiators in Patients with Rheumatoid Arthritis: A Multi-database Cohort Study
Ajinkya Pawar ¹, Rishi Desai ¹, Nileesa Gautam ¹ and Seoyoung C. Kim², ¹Brigham and Women's hospital, Boston, ²Brigham and Women’s Hospital and Harvard Medical School, Boston
Background/Purpose: It is well-known that biologic or targeted synthetic DMARDs increase the risk of serious infections (SIs), but few studies have directly compared the risk…
Abstract Number: 549 • 2019 ACR/ARP Annual Meeting
US Rheumatologists’ Beliefs and Knowledge About Biosimilars – an Ongoing Survey
Allan Gibofsky¹, Dorothy McCabe ² and Sam Badawi ², ¹Weill Cornell Medical College, New York, NY, ²Boehringer Ingelheim, Ridgefield, CT
Background/Purpose: A systematic review of survey literature from 2014-2018 found that clinicians in the US and Europe are cautious about biosimilar use (JMCP; 2019;25:102). We…
Abstract Number: 2911 • 2019 ACR/ARP Annual Meeting
A Randomised, Open Labelled Clinical Trial to Investigate Synovial Mechanisms Determining Response – Resistance to Rituximab versus Tocilizumab in Rheumatoid Arthritis Patients Failing TNF Inhibitor Therapy
Frances humby ¹, Maya H. Buch ², Patrick Durez ³, Myles Lewis ¹, Michele Bombardieri ¹, Hasan Rizvi ⁴, Stephen Kelly ⁴, Liliane Fosatti ¹, Rebecca Hands ¹, Giovanni Giorli ¹, Arti Mahto ¹, Carlomaurizio Montecucco ⁵, Bernard Lauwerys ⁶, Vasco Romao ⁷, Arthur Pratt ⁸, Serena Bugatti ⁹, Nora Ng ¹⁰, Felice Rivellese ¹, Pauline Ho ¹¹, Mattia Bellan ¹², Mattia Congia ¹³, Patrick Verschueren ¹⁴, Pier Paolo Sainaghi ¹², Nagui Gendi ¹⁵, Bhaskar Dasgupta ¹⁶, Alberto Cauli ¹⁷, Piero Reynolds ¹⁸, Juan Cañete ¹⁹, Robert J. Moots ²⁰, Peter Taylor ²¹, Christopher Edwards ²², John Isaacs ⁸, Peter Sasieni ²³, João Eurico Fonseca ²⁴, Ernest Choy ²⁵ and Costantino Pitzalis²⁶, ¹Queen Mary University of London, London, United Kingdom, ²University of Leeds & NIHR Leeds Biomedical Research Centre, Leeds, United Kingdom, ³Pôle de Recherche en Rhumatologie, Institut de Recherche Expérimentale et Clinique, UCL Saint-Luc, Brussels, Belgium, ⁴Barts Health NHS Trust, London, United Kingdom, ⁵Department of Rheumatology, IRCCS Policlinico S. Matteo Foundation, University of Pavia, Pavia, Italy, Pavia, Italy, ⁶University of Louvain, Louvain, Belgium, ⁷University of Lisbon, Lisbon, Portugal, ⁸University of Newcastle, Newcastle, United Kingdom, ⁹University of Pavia, Pavia, Italy, ¹⁰Guys and St Thomas NHS Trust, London, United Kingdom, ¹¹University of Manchester, Manchester, United Kingdom, ¹²University of Novara, Novara, Italy, ¹³University of Cagliari, Cagliari, Italy, ¹⁴University of Leuven, Leuven, Belgium, ¹⁵Basildon Hospital NHS Trust, Basildon, United Kingdom, ¹⁶Southend University Hospital, NHS Foundation Trust, Westcliff-on-Sea, United Kingdom, ¹⁷Rheumatology Unit, University Clinic AOU and University of Cagliari, Cagliari, Italy, ¹⁸Homerton University NHS Trust, London, United Kingdom, ¹⁹Rheumatology Department, Hospital Clínic and IDIBAPS,, Barcelona, Spain, ²⁰Institute of Ageing and Chronic Disease, Liverpool, United Kingdom, ²¹University of Oxford, Oxford, United Kingdom, ²²University of Southampton, Southampton, United Kingdom, ²³Kings College London, London, United Kingdom, ²⁴Rheumatology and Bone Diseases Department, Hospital de Santa Maria, Centro Hospitalar Universitário Lisboa Norte; Unidade de Investigação em Reumatologia, Instituto de Medicina Molecular, Faculdade de Medicina, Universidade de Lisboa; Centro Académico de Medicina de Lisboa; Lisbon, Portugal., Lisbon, Portugal, ²⁵Cardiff University School of Medicine, Cardiff, United Kingdom, ²⁶Centre for Experimental Medicine & Rheumatology, Queen Mary University of London, London, United Kingdom
Background/Purpose: Although biologic therapies have transformed the outlook for rheumatoid arthritis (RA), the lack of a major treatment response in over 50% of patients, the…
Abstract Number: 824 • 2019 ACR/ARP Annual Meeting
Results from a Randomized Controlled Trial of the Safety of the Live Varicella Vaccine in TNF-Treated Patients
Jeffrey Curtis¹, S Louis Bridges ², Stacey S Cofield ², John Bassler ¹, Theresa Ford ³, Stephen Lindsey ⁴, Alan Kivitz ⁵, Ilhem Messaoudi ⁶, Kaleb Michaud ⁷, Joseph Huffstutter ⁸, Ted Mikuls ⁹, David Ridley ¹⁰, William Shergy ¹¹, Sarah Siegel ¹² and Kevin Winthrop ¹³, ¹University of Alabama at Birmingham, Birmingham, AL, ²University of Alabama at Birmingham, Birmingham, ³North Georgia Rheumatology Group, PC, Lawrenceville, GA, ⁴Ochsner Clinic Foundation, Baton Rouge, LA, ⁵Altoona Center for Clinical Research, Duncansville, PA, ⁶University of California Irvine, Irvine, CA, ⁷University of Nebraska Medical Center, Omaha, NE, ⁸Arthritis Associates, Hixon, TN, ⁹VA Nebraska-Western IA Health Care System & University of Nebraska Medical Center, Omaha, NE, ¹⁰St. Paul Rheumatology, Eagan, MN, ¹¹Rheumatology Associates of North Alabama, Huntsville, AL, ¹²Oregon Health Science University, Portland, OR, ¹³Oregon Health and Science University, Portland, OR
Background/Purpose: There has been minimal evaluation of the safety of live virus vaccines in patients receiving biologic therapies who may be immunocompromised. The Varicella Zoster…
Abstract Number: 835 • 2019 ACR/ARP Annual Meeting
High Baseline Patient’s Compared with Evaluator’s Global Assessment Is Associated with Lower Retention and Remission Rates of First TNF Inhibitor in Psoriatic Arthritis Patients – Data from the EuroSpA Research Collaboration Network
Brigitte Michelsen¹, Lykke Midtbøll Ørnbjerg ², Herman Mann ³, Tore Kvien ⁴, Michael J. Nissen ⁵, Maria José Santos ⁶, Dan Nordström ⁷, Lennart Jacobsson ⁸, Ziga Rotar ⁹, Bjorn Gudbjornsson ¹⁰, Süleyman Serdar Koca ¹¹, Catalin Codreanu ¹², Manuel Pombo-Suarez ¹³, Irene van der Horst-Bruinsma ¹⁴, Anne Gitte Loft ¹⁵, Karel Pavelka ³, Eirik Kristianslund ¹⁶, Burkhard Moeller ¹⁷, Elsa Vieira-Sousa ¹⁸, Anna Mari Hokkanen ¹⁹, Ulf Lindström ²⁰, Matija Tomsic ²¹, Thorvardur J Love ²², Abdurrahman Tufan ²³, Ruxandra IONESCU ²⁴, Carlos Sánchez-Piedra ²⁵, Marleen van de Sande ²⁶, Gary Macfarlane ²⁷, Florenzo Iannone ²⁸, Lise Hyldstrup ², Mikkel Østergaard ²⁹ and Merete Lund Hetland ³⁰, ¹Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Rigshospitalet Glostrup, Denmark/ Hospital of Southern Norway Trust, Kristiansand, Norway/ Diakonhjemmet Hospital, Oslo, Norway, Oslo, Norway, ²Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Rigshospitalet Glostrup, Denmark, Copenhagen, Denmark, ³Institute of Rheumatology, Department of Rheumatology, 1st Faculty of Medicine, Prague, Czech Republic, Prague 2, Czech Republic, ⁴Diakonhjemmet Hospital, Dept. of Rheumatology / University of Oslo, Faculty of Medicine, Oslo, Norway, ⁵University Hospital Geneva, Geneva, Switzerland, ⁶Rheumatology department, Hospital Garcia de Orta, Almada, Portugal, ⁷Department of Medicine, ROB-FIN, Helsinki University Hospital and Helsinki University, Helsinki, Finland., Helsinki, Finland, ⁸Dept of Rheumatology and Inflammation Research, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Sweden,, Gothenburg, Sweden, ⁹UMC LJUBLJANA, DPT. OF RHEUMATOLOGY, LJUBLJANA, Slovenia, ¹⁰Centre for Rheumatology Research, Landspitali and Faculty of Medicine, University of Iceland, Reykjavik, Iceland, ¹¹Fırat University School of Medicine Division of Rheumatology, Elazığ, Turkey, ¹²Center of Rheumatic Diseases, University of Medicine and Pharmacy, Bucharest, Romania., Bucharest, Romania, ¹³Unit Research, Spanish Society of Rheumatology, Madrid, Spain, ¹⁴Amsterdam University Medical Center, Amsterdam, Netherlands, ¹⁵Department of Rheumatology, Aarhus University Hospital, Aarhus, Denmark, Århus, Denmark, ¹⁶Department of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway., Oslo, Norway, ¹⁷University Hospital Bern, Bern, Switzerland, ¹⁸Rheumatology and Metabolic Bone Diseases, Hospital de Santa Maria - Centro Hospitalar Lisboa Norte, EPE | Rheumatology Research Unit, Instituto de Medicina Molecular - Faculty of Medicine, University of Lisbon, Lisbon Academic Medical Centre, Lisbon, Portugal,, Lisbon, Portugal, ¹⁹Helsinki University Hospital, Helsinki, Finland, ²⁰University of Gothenburg, Gothenburg, Sweden, ²¹Department of Rheumatology, University Medical Center Ljubljana, Slovenia, Ljubljana, Slovenia, ²²Faculty of Medicine, University of Iceland, Reykjavik, Iceland, ²³Division of Rheumatology, Gazi University School of Medicine, Ankara, Turkey, Ankara, Turkey, ²⁴SPITALUL CLINIC SFANTA MARIA, Bucharest, ²⁵Research Unit, Spanish Society of Rheumatology, Madrid, Spain, ²⁶Amsterdam UMC, Amsterdam, Netherlands, ²⁷University of Aberdeen, Aberdeen, United Kingdom, ²⁸Department of Emergency and Transplantation , Rheumatology Unit, University Hospital of Bari, Bari, Italy., Bari, Italy, ²⁹Copenhagen Center for Arthritis Research, University of Copenhagen, Copenhagen, Denmark, ³⁰DANBIO and Copenhagen Center for Arthritis Research (COPECARE), Center for Rheumatology and Spine Diseases, Centre of Head and Orthopaedics, Rigshospitalet, Copenhagen, Denmark
Background/Purpose: Discordance between baseline patient’s and evaluator’s global assessment of disease activity is common1 and may reduce the likelihood of remission following tumor necrosis factor…
Abstract Number: 1511 • 2018 ACR/ARHP Annual Meeting
The Relationship between Lipid Profile Changes and Inflammation across the Phase 3 Sarilumab Rheumatoid Arthritis (RA) Developmental Program
Christina Charles-Schoeman¹, Gregory St. John², Henry Leher², Toshio Kimura², Hubert van Hoogstraten³, Michael T. Nurmohamed⁴, Miguel Angel González-Gay⁵ and Edward C. Keystone⁶, ¹Rheumatology, UCLA David Geffen School of Medicine, Los Angeles, CA, ²Regeneron Pharmaceuticals, Inc., Tarrytown, NY, ³Sanofi Genzyme, Bridgewater, NJ, ⁴VU University Medical Center, Amsterdam, Netherlands, ⁵University Hospital Marques de Valdecilla, Santander, Spain, ⁶University of Toronto and Mount Sinai Hospital, Toronto, ON, Canada
Background/Purpose: Sarilumab showed superiority to placebo and adalimumab in Phase 3 trials. Serum lipids may be reduced in the setting of chronic inflammation associated with…
Abstract Number: 2530 • 2018 ACR/ARHP Annual Meeting
Uncovering Clinicians’ Gaps and Attitudes Toward Biosimilars: Impact of a 2-Phase Educational Program
Zachary Schwartz¹, Jenny Schulz¹, Angelique Vinther¹, Alyce Kuklinski¹ and Kenneth Saag², ¹Clinical Care Options, Reston, VA, ²University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Biosimilar agents have changed the clinical landscape in rheumatology, gastroenterology, and dermatology. We sought to measure clinicians’ competence and knowledge of biosimilars and to…
Abstract Number: 1528 • 2018 ACR/ARHP Annual Meeting
Unique Changes in Hemoglobin with Sarilumab Versus Adalimumab Are Independent of Better Disease Control in Patients with Rheumatoid Arthritis (RA)
Gerd R. Burmester¹, Owen Hagino², Qunming Dong³, Marina Stanislav⁴, Antonio Gomez-Centeno⁵, Carlo Selmi⁶, Tom W.J. Huizinga⁷, Erin Mangan⁸, Cem Gabay⁹ and Mark C. Genovese¹⁰, ¹Charité – University Medicine Berlin, Free University and Humboldt University Berlin, Berlin, Germany, ²Sanofi Genzyme, Bridgewater, NJ, ³Sanofi, Bridgewater, NJ, ⁴Scientific Research Institute of Rheumatology, Russian Academy of Medical Sciences, Moscow, Russian Federation, ⁵Corporació Sanitària Parc Taulí, Barcelona, Spain, ⁶Rheumatology and Clinical Immunology Unit, Humanitas Research Hospital, Rozzano (MI), Italy, ⁷Leiden University Medical Center, Leiden, Netherlands, ⁸Regeneron Pharmaceuticals, Inc., Tarrytown, NY, ⁹University Hospitals of Geneva, Geneva, Switzerland, ¹⁰Stanford University Medical Center, Palo Alto, CA
Background/Purpose: Anemia (WHO criteria: Hemoglobin [Hb] levels <12.0 g/dL [females] or <13.0 g/dL [males]) is a common finding associated with increased joint inflammation in patients…
Abstract Number: 2539 • 2018 ACR/ARHP Annual Meeting
SB4 Shows Comparable Short-Term Effectiveness to Its Etanercept Originator As First-Line Biologic Treatment for Patients with Rheumatoid Arthritis in Routine Clinical Care
Diederik De Cock¹, Lianne Kearsley-Fleet², Rebecca Davies², Kath Watson² and Kimme L. Hyrich^1,3, ¹Arthritis Research UK Centre for Epidemiology, The University of Manchester, Manchester, United Kingdom, ²Arthritis Research UK Centre for Epidemiology, The University of Manchester, Manchester Academic Health Science Centre, Manchester, United Kingdom, ³National Institute of Health Research Manchester Biomedical Research Centre, Manchester University NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, United Kingdom
Background/Purpose: In the United Kingdom (UK) since 2016, etanercept biosimilars (SB4) are since 2016 a first-line treatment option for the management of severe rheumatoid arthritis…
Abstract Number: 1533 • 2018 ACR/ARHP Annual Meeting
Simulating Population Disability Outcomes for Alternative Treatment Pathways in Patients with Active Rheumatoid Arthritis
Josephine Mauskopf¹, Mahdi Gharaibeh², David Wamble¹, David H. Collier², Bradley S. Stolshek² and Eric L. Matteson³, ¹RTI Health Solutions, Research Triangle Park, NC, ²Amgen Inc., Thousand Oaks, CA, ³Division of Rheumatology, Mayo Clinic College of Medicine and Science, Rochester, MN
Background/Purpose: Rheumatoid arthritis (RA) is a chronic, systemic inflammatory disorder that causes joint pain and swelling, bone erosions, and deformity. This debilitating disease can severely…
Abstract Number: 2559 • 2018 ACR/ARHP Annual Meeting
Efficacy and Safety of Ixekizumab in Patients with Active Psoriatic Arthritis and Previous Inadequate Response to TNF Inhibitors: Two-Year Follow-up from a Phase 3 Study
Ana-Maria Orbai¹, Amanda M. Gellett², Lisa Kerr² and Arnaud Constantin³, ¹Johns Hopkins University School of Medicine, Baltimore, MD, ²Eli Lilly and Company, Indianapolis, IN, ³Hopital Pierre-Paul Riquet, Toulouse, France
Background/Purpose: Ixekizumab (IXE), a high-affinity monoclonal antibody that selectively targets IL-17A, was superior to placebo (PBO) at Week (Wk) 24 for treating PsA signs and…
Abstract Number: 1534 • 2018 ACR/ARHP Annual Meeting
Comparative Risk of Diabetes Mellitus in Rheumatoid Arthritis Patients Treated with Different Biologics- a Cohort Study
Rishi J. Desai¹, Sara Dejene², Yinzhu Jin², Jun Liu³ and Seoyoung C. Kim², ¹Division of Pharmacoepidemiology and Pharmacoeconimics, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ²Brigham and Women's Hospital, Boston, MA, ³Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women's Hospital, Boston, MA
Background/Purpose: Patients with rheumatoid arthritis (RA) often develop diabetes mellitus (DM), potentially due to aggravated systemic inflammation. Reducing inflammation with disease-modifying antirheumatic drugs (DMARD) may…
Abstract Number: 2596 • 2018 ACR/ARHP Annual Meeting
Real-World Long-Term Effectiveness of Switching between Tumor Necrosis Factor Inhibitors in Psoriatic Arthritis Patients from the Rheumatic Diseases Portuguese Register
Elsa Vieira-Sousa^1,2, Mónica Eusébio³, Pedro Ávila-Ribeiro^1,2, Nikita Khmelinskii^1,2, Ana Rita Machado^1,2, Teresa Martins-Rocha^4,5, Miguel Bernardes^4,5, Daniela Santos Faria⁶, Joana Leite Silva⁶, Helena Santos⁷, Cláudia Miguel⁷, Pedro Carvalho^8,9, Tiago Costa¹⁰, Lídia Teixeira¹¹, Tiago Meirinhos¹², Patrícia Nero¹³ and Maria José Santos^11,14, ¹Serviço de Reumatologia e Doenças Ósseas Metabólicas, Hospital de Santa Maria, Centro Hospitalar Lisboa Norte, Lisboa, Portugal, Lisboa, Portugal, ²Unidade de Investigação em Reumatologia, Instituto de Medicina Molecular, Faculdade de Medicina, Universidade de Lisboa, Centro Académico de Medicina de Lisboa, Lisboa, Portugal, Lisboa, Portugal, ³Sociedade Portuguesa de Reumatologia, Lisboa, Portugal, LIsboa, Portugal, ⁴Serviços de Reumatologia do Centro Hospitalar São João do Porto, Porto, Portugal, Porto, Portugal, ⁵Faculdade de Medicina da Universidade do Porto (FMUP), Porto, Portugal, Porto, Portugal, ⁶Serviço de Reumatologia da Unidade Local de Saúde do Alto Minho, Ponte de Lima, Portugal, Ponte de Lima, Portugal, ⁷Instituto Português de Reumatologia Lisboa, Portugal, Lisboa, Portugal, ⁸Serviço de Reumatologia, Hospitais Universitários de Coimbra, Coimbra, Portugal, Coimbra, Portugal, ⁹Serviço de Reumatologia, Centro Hospitalar e Universitário do Algarve, Faro, Portugal, Faro, Portugal, ¹⁰Serviço de Reumatologia do Hospital Egas Moniz, Lisboa, Portugal, Lisboa, Portugal, ¹¹Serviço de Reumatologia do Hospital Garcia de Orta, Almada, Portugal, Almada, Portugal, ¹²Serviço de Reumatologia, Centro Hospitalar do Baixo Vouga, Aveiro, Portugal, Aveiro, Portugal, ¹³Hospital CUF Descobertas, Lisboa, Portugal, Lisboa, Portugal, ¹⁴Sociedade Portuguesa de Reumatologia, Lisboa, Portugal, Lisboa, Portugal
Background/Purpose: Tumor necrosis factor inhibitors (TNFi) lead to a dramatic improvement in the management of psoriatic arthritis (PsA). Nevertheless, a significant proportion of patients…
Abstract Number: 1610 • 2018 ACR/ARHP Annual Meeting
Incremental Benefits to Quality of Life Associated with Achieving Higher Levels of American College of Rheumatology Response and Skin Clearance in Patients with Psoriatic Arthritis
Josef S. Smolen¹, David Shrom², Chen-Yen Lin², Julie Birt², Georg Schett³ and Alice B Gottlieb⁴, ¹Division of Rheumatology, Department of Medicine 3, Medical University of Vienna, Vienna, Austria, ²Eli Lilly and Company, Indianapolis, IN, ³Medical Clinic 3, Friedrich-Alexander University, Erlangen-Nuremberg, Germany, ⁴Department of Dermatology, New York Medical College, New York, NY
Background/Purpose: PsA is a chronic inflammatory disease associated with psoriasis. For optimal quality of life (QoL) improvements, all PsA symptoms should be managed. We examine…
Abstract Number: 2610 • 2018 ACR/ARHP Annual Meeting
Certolizumab Pegol Serum Levels ≥20 Mg/L Are Associated with Treatment Response in Patients with Axial Spondyloarthritis
Johanna Gehin¹, Silje Watterdal Syversen², Guro Løvik Goll², David J Warren¹, Joseph Sexton³, Eldri Kvein Strand⁴, Tore Kvien^3,5,6, Elisabeth Lie^2,6 and Nils Bolstad⁷, ¹Department of Medical Biochemistry, OUS-Radiumhospitalet, Oslo, Norway, ²Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ³Dept. of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ⁴Lillehammer Revmatismesykehus, Lillehammer, Norway, ⁵NOR-DMARD, EuroSpA Research Collaboration Network, Oslo, Norway, ⁶On behalf of the NOR-DMARD registry, Oslo, Norway, ⁷Department of Medical Biochemistry,, OUS-Radiumhospitalet, Oslo, Norway
Background/Purpose: Measurement of serum drug levels can help clinicians tailor treatment with TNF-inhibitors.An association between certolizumab pegol (CP) serum levels and response has previously been…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.